Orthofix Medical stock reports USD 210.93 million revenue
Orthofix Medical (OFIX) reported second-quarter 2026 revenue of USD 210.93 million, exceeding forecasts, despite an adjusted EPS loss of USD 0.39. Stifel maintained its USD 13.00 price target and Buy rating, citing profitable growth and commercial execution. The company raised its full-year sales and adjusted EBITDA guidance due to improved sales trends and Medicare reimbursement benefits, though profitability remains a key challenge.
Form 4 Orthofix Medical Inc For: 27 September By Investing.com
This article from Investing.com is a regulatory filing update, specifically a Form 4 for Orthofix Medical Inc., dated September 27. It provides no further details about the filing's content. The rest of the page is filled with various market data, news headlines, and promotional content from Investing.com.
Juniper investment company sells $2.73m of Orthofix Medical shares By Investing.com
Juniper Investment Company, a 10% owner and director of Orthofix Medical Inc. (NASDAQ:OFIX), recently sold 310,000 shares of common stock for approximately $2.73 million across two transactions in September 2026. Despite the sell-off, Orthofix Medical's stock has seen an 8.4% gain in the past week, though it remains down 38% year-to-date. Analysts believe the stock is undervalued and predict profitability this year, following a stronger-than-expected Q2 2026 performance and raised guidance.
Juniper investment company sells $2.73m of Orthofix Medical shares By Investing.com
Juniper Investment Company, a major owner and director of Orthofix Medical Inc. (NASDAQ:OFIX), recently sold 310,000 shares of the company's common stock for approximately $2.73 million across two transactions in September 2026. Despite these sales, the stock has shown an 8.4% gain in the past week, though it remains down 38% year-to-date. InvestingPro analysis suggests Orthofix is currently undervalued and poised for profitability this year, following a stronger-than-expected Q2 2026 financial performance.
Form 4 Orthofix Medical Inc For: 27 September By Investing.com
This article reports on the filing of Form 4 by Orthofix Medical Inc. for September 27. It appears to be a standard financial news brief from Investing.com, providing basic information about the SEC filing for the company.
Juniper investment company buys $2.73m in Orthofix shares By Investing.com
Juniper Investment Company, LLC, a major owner and director of Orthofix Medical Inc. (NASDAQ:OFIX), recently purchased 310,000 shares for approximately $2.73 million in mid-September. The stock has since increased by 8.4%, and InvestingPro analysis suggests OFIX remains undervalued with a Fair Value of $12.89. These transactions align with Orthofix's positive Q2 2026 results and raised full-year guidance, despite ongoing challenges with smaller U.S. spine distributors.
Former Orthofix Execs Fired Over Tawdry Texts Awarded $24.5M
An arbitrator has awarded $24.5 million to three former Orthofix Medical executives who were fired "for cause" in 2023. The executives were terminated for sending "sophomoric and vulgar text messages among themselves on their private phones." Olshan partner Kyle Bisceglie noted that there was little legal precedent for invoking a "moral turpitude clause" based on private communications that didn't outwardly impact workplace conduct.
A fund bought Orthofix Medical (OFIX) shares twice in September. The second purchase was larger.
Juniper Targeted Opportunity Fund, L.P. acquired shares of Orthofix Medical Inc. (OFIX) twice in September 2026. The fund bought 120,000 shares on September 18 at $8.7393 each, and a larger block of 190,000 shares on September 21 at $8.8599 per share. Juniper Investment Company, along with John A. Bartholdson and Alexis P. Michas, were identified as 10% owners and managing members, disclaiming beneficial ownership except for their pecuniary interests.
Stifel reiterates Orthofix Medical stock rating with $13 target
Stifel maintained its Buy rating on Orthofix Medical Inc. (NASDAQ: OFIX) with an unchanged $13.00 price target, citing profitable growth and attractive valuation. The firm highlighted the company's 7D FLASH product benefiting from essential tremor tailwinds and improved commercial execution. Orthofix recently surpassed Q2 2026 earnings expectations, raised its full-year guidance, and secured a European distributor arrangement, despite ongoing challenges with smaller U.S. spine distributors.
Stifel reiterates Orthofix Medical stock rating with $13 target By Investing.com
Stifel maintained its Buy rating on Orthofix Medical Inc. (NASDAQ:OFIX) shares with a $13.00 price target, citing profitable growth and attractive valuation. The company's 7D FLASH product and improved commercial execution are key drivers, while InvestingPro Tips predict profitability this year with an EPS forecast of $0.69. Orthofix recently surpassed Q2 2026 expectations, raising full-year guidance due to improved sales and Medicare reimbursement.
Orthofix Medical (OFIX) officer sells shares in preset trading plan
Orthofix Medical Inc. (OFIX) officer Patrick Fisher, President, Global Limb Recon, sold 150 shares of common stock at $9.39 per share on September 1, 2026. This transaction was conducted under a pre-set Rule 10b5-1 trading plan adopted on May 29, 2026. Following the sale, Fisher directly holds 51,069 shares, which include 36,028 restricted stock units.
Orthofix Medical's Patrick Fisher Sells 150 Shares Under Rule 10b5-1 Trading Plan
Patrick Fisher, President of Global Limb Recon at Orthofix Medical Inc. (NASDAQ: OFIX), sold 150 shares of company common stock on September 1, 2026, at $9.39 per share. This transaction was executed under a Rule 10b5-1 trading plan established on May 29, 2026. Following the sale, Fisher maintains beneficial ownership of 51,069 shares, including previously reported restricted stock units.
Orthofix Medical (OFIX) Stock Sees Fair Value Cut After Analysts Trim Q2 Outlook
Analysts have revised down the fair value and price targets for Orthofix Medical (OFIX) stock from US$15 to US$13, citing updated projections for revenue and cash generation, alongside the impact of the MDR transition. Despite the cuts, many analysts maintain a "Buy" or "Outperform" rating, indicating a continued constructive long-term outlook for the company, although specific factors like lower expected cash generation and weaker spine distributor performance contributed to the bearish adjustments.
Orthofix president Patrick Fisher sells $13,066 in stock
Patrick Fisher, President, Global Limb Recon at Orthofix Medical Inc. (NASDAQ: OFIX), sold 1,295 shares of the company's common stock for $13,066 to cover tax withholding obligations for restricted stock units. Following the transaction, Fisher beneficially owns 51,219 shares. This sale comes as Orthofix recently surpassed Wall Street expectations for its second-quarter 2026 earnings and raised its full-year guidance.
Orthofix (OFIX) insider sale tied to RSU tax withholding
Patrick Fisher, President, Global Limb Recon at Orthofix Medical Inc. (OFIX), sold 1,295 shares of common stock at $10.09 per share on August 18, 2026. This sale was a mandatory "sell-to-cover" transaction to satisfy tax withholding obligations related to restricted stock units and was not discretionary. Following the sale, Fisher directly holds 51,219 shares, including restricted stock units and shares acquired through Orthofix’s Stock Purchase Plan.
Juniper investment sells $402,744 in Orthofix Medical shares By Investing.com
Juniper Investment Company, LLC, a 10% owner and director of Orthofix Medical Inc. (NASDAQ:OFIX), recently sold $402,744 worth of the company's common stock in August 2026. Despite the sales and a year-to-date stock decline, InvestingPro analysis suggests Orthofix Medical is undervalued, with analysts forecasting profitability in the coming year. These transactions occurred across two dates, with shares sold at weighted average prices of $10.3838 and $10.013.
Juniper investment sells $402,744 in Orthofix Medical shares By Investing.com
Juniper Investment Company, a 10% owner and director of Orthofix Medical Inc. (NASDAQ:OFIX), sold 39,500 shares totaling $402,744 in two August 2026 transactions. Despite the sales and a 33% year-to-date stock decline, InvestingPro analysis suggests OFIX is undervalued, with analysts forecasting profitability for the current year. Juniper Investment Company retains significant holdings in Orthofix Medical through various funds.
Orthofix Medical (NASDAQ: OFIX) logs new insider trades
Orthofix Medical Inc. (NASDAQ: OFIX) has reported new insider trading activity through a Form 4 filing. The filing indicates sales of 39,500 shares of common stock totaling approximately $403K by insiders Juniper Investment Company, LLC, Bartholdson John A., and Michas Alexis P., all identified as 10% owners. These transactions, primarily sales, occurred between August 14 and August 17, 2026, and represent a negative sentiment and moderate impact according to Rhea-AI's analysis.
Juniper Investment Company reports Orthofix Medical share disposal worth $402,483.1
Juniper Investment Company, a 10% owner of Orthofix Medical, recently purchased 39,500 common shares of Orthofix Medical between August 14-17, 2026, for approximately $402,483.1. These purchases, priced at about $10.38 and $10.01 per share, increased Juniper Multi-Strategy Fund's stake to 84,926 shares. Juniper also holds significant indirect shares through Juniper Targeted Opportunities and Juniper Targeted Opportunity Fund.
Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook
Orthofix Medical's updated outlook reflects a rebound in bone growth stimulation reimbursement and improving trends in biologics and limb reconstruction, partially offset by a steeper-than-expected decline in its smaller U.S. spine distributor segment. The company anticipates third-quarter revenue to be similar to the second quarter, with modest year-over-year EBITDA margin expansion, and expects a significant European inventory order in the fourth quarter. Orthofix is also re-strategizing its spine distribution by focusing on larger partners and is advancing its 7D technology platform and VIRATA pedicle screw system.
Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook
Orthofix Medical's updated outlook reflects a rebound in bone growth stimulation reimbursement and improved trends in biologics and limb reconstruction, partially offset by a steeper-than-expected decline among smaller U.S. spine distributors. The company expects third-quarter revenue to be similar to the second quarter with modest EBITDA margin expansion, driven by internal executive oversight for the spine business and strategic distribution focusing on larger partners. While a significant European stocking order is anticipated, management has withdrawn free cash flow guidance due to timing, emphasizing organic growth and balance sheet strengthening over M&A.
CCORF Maintains Orthofix Medical(OFIX.US) With Buy Rating, Maintains Target Price $13
CCORF has reiterated its Buy rating for Orthofix Medical (OFIX.US), maintaining a target price of $13. This indicates a continued positive outlook on the company's stock performance by the firm.
Armistice Capital (OFIX) discloses 3.26M-share, 8.01% Orthofix Medical stake
Armistice Capital, LLC and Steven Boyd have reported an updated beneficial ownership stake of 8.01% in Orthofix Medical Inc., totaling 3,264,000 shares. This disclosure, made via an Amendment No. 8 to their Schedule 13G, indicates shared voting and dispositive power over these shares, which are directly held by Armistice Capital Master Fund Ltd. The filing details key figures of their ownership and clarifies the roles and responsibilities concerning these securities.
CCORF Maintains Orthofix Medical(OFIX.US) With Buy Rating, Cuts Target Price to $13
CCORF has reiterated its Buy rating for Orthofix Medical (OFIX.US) but has lowered its target price to $13. This indicates a continued positive outlook on the company despite a revised valuation.
Dimensional Fund Advisors LP Trims Stock Holdings in Orthofix Medical Inc. $OFIX
Dimensional Fund Advisors LP reduced its stake in Orthofix Medical Inc. (NASDAQ:OFIX) by 11.3% in the first quarter, selling 107,566 shares but retaining 841,521 shares valued at approximately $9.65 million. Despite institutional investors owning nearly 90% of the stock, Orthofix Medical continues to face a "Hold" consensus among analysts, with a consensus price target of $16.00. The company recently reported a quarterly loss of $0.39 per share, outperforming analyst estimates, and projects a full-year loss of $1.40 per share.
Orthofix Medical Inc. Q2 2026: Revenue $210.9M, EPS $(0.39) — 10-Q Summary
Orthofix Medical Inc. reported its Q2 2026 financial results, with revenue reaching $210.9 million and a diluted EPS of $(0.39). This represents a 3.8% year-over-year revenue increase, driven by strong performance in spine fixation and limb reconstruction. The company is strategically discontinuing M6 artificial discs and prioritizing recurring product revenue over capital equipment sales.
Orthofix Medical Inc. (OFIX): Analyzing the 34.43% Potential Upside in the Medical Devices Sector
Orthofix Medical Inc. (NASDAQ: OFIX) is a medical devices company with a projected 34.43% potential upside, according to analyst consensus. Despite financial challenges like negative EPS and ROE, the company is seen as undergoing a transformation with strategic investments in product development, particularly in bone growth stimulation and spinal fixation implants. Analyst sentiment is largely positive, suggesting potential for enhanced profitability and shareholder value, though investors should consider the short-term overbought technical indicators and inherent risks.
Orthofix Medical (OFIX) Stock Sinks As One Off Growth Clouds Outlook
Orthofix Medical's stock dropped 15% despite management raising full-year revenue and adjusted EBITDA guidance. While the company showed progress in profitability and growth in specific product areas, concerns remain regarding the quality and concentration of its revenue, including a one-off European distributor purchase that will create a revenue headwind in 2027. Investors are weighing the potential for a turnaround against ongoing losses and execution risks.
Orthofix Medical Q2 Earnings Call Highlights
Orthofix Medical reported improving Q2 operating trends with 5% pro forma constant-currency net sales growth, despite continued weakness from smaller U.S. spine distributors. The company saw strong growth in global limb reconstruction and spine fixation, stabilized biologics, and benefits from restored Medicare reimbursement for bone growth stimulators. Orthofix raised its full-year 2026 net sales and adjusted EBITDA outlooks, with a strategic European distributor arrangement expected to boost Q4 sales.
Orthofix Medical (OFIX) Stock Sinks As One Off Growth Clouds Outlook
Orthofix Medical (OFIX) saw its stock drop by about 15% despite reporting increased Q2 revenue and narrowed net loss per share, prompting mixed reactions from investors. The company's Q2 revenue was US$210.9 million, and management raised full-year revenue and adjusted EBITDA guidance. However, concerns about the quality of growth, particularly a one-off European distributor inventory purchase, and concentration risks in its Spine Fixation segment are weighing on its outlook.
Earnings call transcript: Orthofix tops Q2 2026 estimates, lifts outlook
Orthofix (OFIX) reported Q2 2026 results that surpassed analyst estimates, driven by improving sales trends and the restoration of Medicare reimbursement. The medical-device maker also raised its full-year sales and adjusted EBITDA guidance. Despite ongoing challenges with smaller U.S. spine distributors, the company highlighted progress in its limb reconstruction and biologics segments and remains focused on profitable growth and disciplined investment.
Orthofix Medical Q2 Earnings Call Highlights
Orthofix Medical reported improving Q2 operating trends with 5% pro forma constant-currency net sales growth, excluding discontinued M6 artificial disc products, driven by global limb reconstruction and spine fixation. Despite strong performance from its top 30 distributors, smaller U.S. spine distributors posed a challenge, leading to a focus on consolidating revenue with high-performing partners. The company raised its full-year 2026 net sales outlook to $845 million to $855 million and adjusted EBITDA to $95 million to $98 million, partly due to a strategic arrangement with a European distributor.
Orthofix Medical Releases Q2 2026 Financial Results
Orthofix Medical Inc. (OFIX) reported Q2 2026 financial results, showing a diluted loss of $0.39 per share, significantly wider than the anticipated $0.03 loss. Despite the earnings shortfall with a net loss of $15.8M, the company's revenue reached $210.9M, surpassing estimates by 0.8% and representing a 3.8% increase year-over-year. Management provided full-year revenue guidance between $845.0M and $855.0M, and analyst sentiment remains mixed but leaning positive.
Orthofix Medical Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:OFIX) 2026-08-05
Orthofix Medical Inc. (OFIX) released its Q2 2026 earnings call presentation on August 5, 2026. The company reported an EPS of $0.07, beating estimates by $0.10, and revenue of $210.93M, which was a 3.85% year-over-year increase and beat estimates by $1.66M. The presentation provides details related to these financial results.
(OFIX) Movement as an Input in Quant Signal Sets
This article analyzes Orthofix Medical Inc. (NASDAQ: OFIX) using quantitative research, highlighting a potential short setup with an exceptional risk-reward ratio. It details various institutional trading strategies (Position, Momentum Breakout, Risk Hedging) and provides a multi-timeframe signal analysis, showing divergent sentiment across near, mid, and long-term horizons. The report suggests choppy conditions for the stock.
Orthofix Number of Employees 2026 | Employee Count & Headcount Data
Orthofix, Inc. had approximately 1,287 employees worldwide as of March 2026, marking a 9.9% growth since 2023 but a 0.4% year-over-year decrease from 2025. The company, headquartered in McKinney, Texas, is actively hiring with 84 active job postings in 2026 and an average employee salary of $106,815. Its workforce is primarily located in the United States (76.6%), with Finance and Operations being the largest functional group.
Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for
Analysts expect Orthofix (OFIX) to report a year-over-year decline in earnings for the quarter ended June 2026, despite anticipating higher revenues. The company is projected to post a quarterly loss of $0.03 per share on revenues of $209.51 million. While the stock currently holds a Zacks Rank #2, its Earnings ESP of 0% suggests it's difficult to conclusively predict an earnings beat.
Orthofix Medical Inc (OFIX) Institutional Confidence
The article analyzes the institutional confidence in Orthofix Medical Inc (OFIX), highlighting its strong position in the Healthcare Equipment & Supplies industry. With an institutional shareholding score of 10.00, OFIX ranks highly, and its institutional shareholding proportion has increased by 4.24% quarter-over-quarter. Key institutional shareholders and changes in their holdings are also detailed.
OFIX|Orthofix Medical Inc|Price:11.770|Chg%:-0.020
This article provides a comprehensive stock analysis of Orthofix Medical Inc (OFIX), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. It notes strong institutional ownership, a "Buy" rating from multiple analysts with a target price of $15.50, and stable stock price expectations in the medium term. The analysis is based on TradingKey's proprietary stock score, which evaluates financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment.
Orthofix Medical Inc. Revenue Breakdown – NASDAQ:OFIX
Orthofix Medical Inc. (NASDAQ: OFIX) generated $822.31 million USD in revenue last year. Its top-performing segment, Global Spine, contributed $687.65 million USD, an increase from the previous year. The United States was the largest geographical contributor, accounting for $684.07 million USD of the total revenue.
Orthofix Medical Inc (OFIX) Cash Flow
This article provides a comprehensive financial overview of Orthofix Medical Inc (OFIX), focusing on its cash flow statements. It details quarterly and annual data for operating, investing, and financing cash flows, including specific figures for net income, capital expenditures, and debt activities. The report also addresses frequently asked questions regarding cash flow components and their significance for OFIX.
Can Orthofix Medical (NASDAQ:OFIX) Capitalize on A Key Medicare Shift?
Orthofix Medical (NASDAQ:OFIX) is back in focus following a Medicare policy reversal regarding the classification of non-invasive bone growth stimulators. This shift is significant for the small-cap spine and orthopedics maker, particularly for its bone growth therapies which are a key product line within its spine business. The article highlights Orthofix Medical's opportunity to capitalize on this change within the medical device sector.
Orthofix Medical Inc (OFIX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Orthofix Medical Inc (OFIX), listing its major shareholders and their respective proportions. It also breaks down shareholder types and provides institutional shareholding data over several quarters. Key shareholders include Engine Capital Management, LP and Juniper Investment Company, LLC.
Orthofix Medical Inc (OFIX) Financial Health: Profitability & Balance Sheet Analysis
Orthofix Medical Inc (OFIX) has a stable financial status with high operating efficiency, reflected in its current financial score of 7.44, ranking 83rd in its industry. The company reported a 1.58% year-over-year increase in quarterly revenue to $196.71M and a substantial 60.62% increase in net profit year-over-year. Key areas like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns also show positive scores.
Orthofix Medical Inc. (OFIX) stock price, news, quote and history
This article provides a comprehensive overview of Orthofix Medical Inc. (OFIX) stock, including its current price, historical data, and key financial metrics. It details the company's operations across its Global Spine and Global Limb Reconstruction segments, highlighting its medical device offerings and market presence. The article also includes performance comparisons against the S&P 500, earnings trends, analyst insights with price targets, and valuation measures.
OFIX|Orthofix Medical Inc|Price:11.260|Chg%:+0.300
Orthofix Medical Inc. (OFIX) is a global medical technology company specializing in spinal hardware, bone growth therapies, and orthopedic solutions. The company's stock currently trades at $11.260, up 2.74%. Its Global Spine segment is the primary revenue driver, generating $440.49M in Q1 2026, accounting for 53.57% of total revenue.
Orthofix Medical Inc. (OFIX) stock price, news, quote and history
This article provides a comprehensive overview of Orthofix Medical Inc. (OFIX) stock, including its current price, historical data, financial performance, and analyst ratings. It details the company's operations in medical devices through its Global Spine and Global Limb Reconstruction segments and offers a comparison with similar companies in the sector. The data presented covers key financial metrics, stock performance over various periods, and upcoming earnings information.
Orthofix Medical (OFIX) Looks Attractive After CMS Reversed Its Reimbursement
Rewey Asset Management highlighted Orthofix Medical Inc. (OFIX) in its Q2 2026 investor letter, noting its attractiveness after the CMS completely reversed a prior reimbursement code change. Despite an earlier setback that led to reduced revenue guidance, the firm views this reversal as a net positive and believes the share decline was overdone. OFIX experienced a 27.03% one-month return, though it is not among the top 40 most popular stocks among hedge funds, and Rewey Asset Management suggests some AI stocks offer greater upside.
MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth
eXeX, a global Surgery Intelligence company, has appointed Max Reinhardt as President, Healthcare, to spearhead the commercial expansion of its Canopus platform across hospital systems in the United States and United Kingdom. Reinhardt, with over three decades of MedTech and pharmaceutical leadership experience, will also oversee the launch of Canopus Command, a new portal offering hospital leadership real-time operational insights into surgical cases. Canopus by eXeX is designed to enhance operating room efficiency by providing real-time, touch-free surgical procedure plans without EHR integration or patient data.
Press Release: Orthofix to Report Second Quarter 2026 Financial Results
Orthofix Medical Inc. (NASDAQ: OFIX) announced it will report its financial results for the second quarter of 2026 after the market closes on Tuesday, July 28, 2026. The company will also host a conference call and live webcast on the same day at 4:30 PM ET to discuss these results and provide a business update.
